BioPharmSignal logoBioPharmSignal

Biotech News

Pacira BioSciences Reports Second Quarter 2026 Financial Results

Pacira BioSciences (PCRX)Pacira BioSciencesEarnings

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30

Related news

PCRXPacira BioSciences2026-04-30 20:01 EST

Pacira BioSciences Reports First Quarter 2026 Financial Results

PCRXPacira BioSciences2026-07-22 12:00 EST

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

View all latest news

Pacira BioSciences

Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine...

Recent company news

PCRXPacira BioSciences2026-08-07 12:00 EST

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PCRXPacira BioSciences2026-08-06 12:00 EST

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

PCRXPacira BioSciences2026-08-04 20:01 EST

Pacira BioSciences Reports Second Quarter 2026 Financial Results

PCRXPacira BioSciences2026-07-28 12:00 EST

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

PCRXPacira BioSciences2026-07-27 12:00 EST

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Stock data

Close
25.58 USD
Market cap
875.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States